A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis

• Justin R. Savage,

  Affiliation GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America

  ⨯
• Abigail Pulsipher,

  Affiliation GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America

  ⨯
• Narayanam V. Rao,

  Affiliation GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America

  ⨯
• Thomas P. Kennedy,

  Affiliations GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America, Pulmonary Diseases Critical Care and Environmental Medicine, School of Medicine, Tulane University, New Orleans, LA, 70112, United States of America

  ⨯
• Glenn D. Prestwich,

  Affiliations GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America, Department of Medicinal Chemistry and Center for Therapeutic Biomaterials, University of Utah, Salt Lake City, UT, 84108, United States of America

  ⨯
• Maria E. Ryan,

  Affiliation Department of Oral Biology and Pathology, School of Dental Medicine, Stony Brook University, Stony Brook, NY, 11794, United States of America

  ⨯
• Won Yong Lee

  * E-mail: lee.wonyong@glycomira.com

  Affiliation GlycoMira Therapeutics, Inc. Salt Lake City, UT, 84108, United States of America

  ⨯